The authors suggest that both the EGFR mutant and those harboring other oncogenic drivers derive from a sub-clonal evolution of oncogene-addicted NSCLCs, keeping the original driver but acquiring further molecular alterations that are typical of de novo SCLC, as mutations in TP53 and RB1 [26]. The gene discussed is TP53; the disease is small cell lung carcinoma.